AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31603012 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (TT4)
Number of subjects: 40
Study 30112726 — intervention group
Group type: EXPERIMENTAL
Intervention: DFN-11 (sumatriptan injection, 3 mg)
Number of subjects: 268
Study 30112726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268
Study 27523501 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 331
Study 25002671 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person AFIX consultation
Number of subjects: 107443
Study 25002671 — intervention group
Group type: EXPERIMENTAL
Intervention: Webinar AFIX consultation
Number of subjects: 107443
Study 25002671 — intervention group
Group type: COMPARATOR
Intervention: Control (no consultation)
Number of subjects: 107443
Study 22773180 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthokeratology (OK)
Number of subjects: 61
Study 22773180 — intervention group
Group type: COMPARATOR
Intervention: Spectacles (SV)
Number of subjects: 61
Study 21144456 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 18
Study 21144456 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture with co-interventions (including NSAIDs or analgesics)
Number of subjects: 18
Study 19195455 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir (DRV/r) 600/100 mg two times a day
Number of subjects: 595
Study 19195455 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/r)
Number of subjects: 595
Study 16606546 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized furosemide (10 mg/m2) plus nebulized salbutamol (0.15 mg/kg)
Number of subjects: 0
Study 16606546 — intervention group
Group type: COMPARATOR
Intervention: Nebulized saline (placebo) plus nebulized salbutamol (0.15 mg/kg)
Number of subjects: 0
Study 12846772 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of iron sucrose administered intravenously over two hours
Number of subjects: 20
Study 12846772 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered intravenously over two hours
Number of subjects: 20
Study 10843158 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH (hPTH 1-34, 200 U in saline over 5 min)
Number of subjects: 34
Study 10843158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 8976035 — intervention group
Group type: EXPERIMENTAL
Intervention: Different blood cardioplegia modes (5 types)
Number of subjects: 109
Study 1451726 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-571 (75 mg)
Number of subjects: 12
Study 1451726 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-571 (300 mg)
Number of subjects: 12
Study 1451726 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-571 (600 mg)
Number of subjects: 12
Study 1451726 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-571 (all doses)
Number of subjects: 12
Study 6391005 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil 50 mg
Number of subjects: 12
Study 6391005 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg
Number of subjects: 12
Study 6391005 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil 50 mg and Nifedipine 10 mg
Number of subjects: 12
Study 6391005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30831456 — intervention group
Group type: EXPERIMENTAL
Intervention: Triangle trocar configuration
Number of subjects: 113
Study 30831456 — intervention group
Group type: COMPARATOR
Intervention: Midline trocar configuration
Number of subjects: 113
Study 28557857 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-mg melatonin supplement
Number of subjects: 10
Study 28557857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 27491280 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg alone
Number of subjects: 42
Study 27491280 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg alone
Number of subjects: 42
Study 27491280 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg plus Dapagliflozin 10 mg coadministered
Number of subjects: 42
Study 24988227 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor adventure program (6-day program including kayaking, surfing, or climbing)
Number of subjects: 0
Study 24988227 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor adventure program (6-day program for participants who took part for the second time)
Number of subjects: 0
Study 24988227 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study 22479985 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined orthodontic/regenerative therapy with immediate orthodontic tooth movement
Number of subjects: 15
Study 22479985 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined orthodontic/regenerative therapy with delayed orthodontic tooth movement
Number of subjects: 15
Study 22479985 — intervention group
Group type: COMPARATOR
Intervention: Regenerative therapy alone (control group)
Number of subjects: 15
Study 19690902 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride desensitizer (Aqua‐Prep F)
Number of subjects: 90
Study 19690902 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan desensitizer (Seal&Protect)
Number of subjects: 90
Study 19690902 — intervention group
Group type: COMPARATOR
Intervention: Control group (VC)
Number of subjects: 90
Study 19690902 — intervention group
Group type: EXPERIMENTAL
Intervention: Variolink II (V)
Number of subjects: 90
Study 17609397 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP-2 (100 microg dose administered intravenously)
Number of subjects: 135
Study 16296916 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic remedies
Number of subjects: 0
Study 16296916 — intervention group
Group type: COMPARATOR
Intervention: RCT methodology
Number of subjects: 0
Study 11892709 — intervention group
Group type: EXPERIMENTAL
Intervention: Periarticular injection of methylprednisoloneacetate and lidocaine (MP group)
Number of subjects: 24
Study 11892709 — intervention group
Group type: COMPARATOR
Intervention: Isotonic sodium chloride and lidocaine (non-MP group)
Number of subjects: 24
Study 10780243 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.2, 0.4 or 0.8 g/kg)
Number of subjects: 27
Study 10780243 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.125, 0.25 or 0.5 mg)
Number of subjects: 27
Study 10780243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 8546280 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 cmH2O pressure support ventilation
Number of subjects: 16
Study 8546280 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 cmH2O pressure support ventilation
Number of subjects: 16
Study 1951242 — intervention group
Group type: EXPERIMENTAL
Intervention: Haptoglobin
Number of subjects: 37
Study 1951242 — intervention group
Group type: COMPARATOR
Intervention: Ethanolamine oleate (Control)
Number of subjects: 37
Study 6167117 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin dipyridamole combination
Number of subjects: 14
Study 6167117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 31810219 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple preload and rice (PA+R)
Number of subjects: 18
Study 31810219 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice with sugar solution preload (PSS+R)
Number of subjects: 18
Study 31810219 — intervention group
Group type: COMPARATOR
Intervention: Rice (control)
Number of subjects: 18
Study 29957283 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-oriented daily physical activity (DPA) assessed using interviewer-administered recall questionnaire (DPA-R) in Cohort 1
Number of subjects: 284
Study 29957283 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-oriented daily physical activity (DPA) assessed using self-administered diary-format daily checklist (DPA-C) in Cohort 2
Number of subjects: 284
Study 29957283 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite score of 6 DPA items (putting on shoes, showering, washing hair, walking for exercise, frequency of walks >10 min, walking on an incline)
Number of subjects: 284
Study 26874291 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure based treatment
Number of subjects: 0
Study 24882460 — intervention group
Group type: EXPERIMENTAL
Intervention: New device for autoinflation
Number of subjects: 45
Study 24882460 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 45
Study 24882460 — intervention group
Group type: EXPERIMENTAL
Intervention: New device for autoinflation (after crossover)
Number of subjects: 45
Study 22760558 — intervention group
Group type: EXPERIMENTAL
Intervention: Almond-containing diet (42 g/d)
Number of subjects: 18
Study 22760558 — intervention group
Group type: EXPERIMENTAL
Intervention: Almond-containing diet (84 g/d)
Number of subjects: 18
Study 22760558 — intervention group
Group type: COMPARATOR
Intervention: Controlled diet (0 g/d)
Number of subjects: 18
Study 19896213 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine/fluoxetine combination treatment
Number of subjects: 0
Study 19896213 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 17166688 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic abdominal perfusion (HAP) with mitomycin C 30mg/m² and cisplatin 60mg/m²
Number of subjects: 22
Study 17166688 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic abdominal perfusion (HAP)
Number of subjects: 22
Study 15277171 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional counseling to increase intake through diet and high-energy supplements
Number of subjects: 36
Study 15277171 — intervention group
Group type: COMPARATOR
Intervention: Standard nutritional counseling (control group)
Number of subjects: 36
Study 11271785 — intervention group
Group type: EXPERIMENTAL
Intervention: Topoisomerase II alpha and II beta expression assessment
Number of subjects: 177
Study 11271785 — intervention group
Group type: COMPARATOR
Intervention: Established prognostic markers (WBC count, CD10 status, sex)
Number of subjects: 177
Study 9544384 — intervention group
Group type: EXPERIMENTAL
Intervention: Thallium-201 (Tl-201)
Number of subjects: 33
Study 9544384 — intervention group
Group type: COMPARATOR
Intervention: Gallium-67 (Ga-67)
Number of subjects: 33
Study 7826222 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozagrel (400 mg/day) for 4 weeks, then DSCG (8 mg/day) for 4 weeks
Number of subjects: 14
Study 7826222 — intervention group
Group type: EXPERIMENTAL
Intervention: DSCG (8 mg/day) for 4 weeks, then Ozagrel (400 mg/day) for 4 weeks
Number of subjects: 14
Study 2979258 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide
Number of subjects: 14
Study 2979258 — intervention group
Group type: COMPARATOR
Intervention: Lidamidine
Number of subjects: 14
Study 2979258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30129080 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy (HBOT) - 30 treatments of 100% oxygen at 2.4 ATA for 80 minutes
Number of subjects: 31
Study 30129080 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment - 30 'sham' treatments, initially pressurized to 1.2 ATA, then cycled between 1.05–1.2 ATA for eight minutes before settling at 1.05 ATA
Number of subjects: 31
Study 30129080 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 31
Study 28477432 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic APR with trans-abdominal individualized levator transection (LAPR-TILT)
Number of subjects: 185
Study 25592656 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin inhalation solution (APT-1026)
Number of subjects: 282
Study 25592656 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin inhalation solution (TIS)
Number of subjects: 282
Study 24018268 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Cognition and Interaction Training (SCIT) plus treatment-as-usual
Number of subjects: 39
Study 24018268 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group (treatment-as-usual only)
Number of subjects: 39
Study 21788905 — intervention group
Group type: EXPERIMENTAL
Intervention: Omocianine (0.1 mg/kg)
Number of subjects: 52
Study 21788905 — intervention group
Group type: EXPERIMENTAL
Intervention: Omocianine (all dose groups)
Number of subjects: 52
Study 18234152 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonological information during training
Number of subjects: 0
Study 18234152 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic information during training
Number of subjects: 0
Study 18234152 — intervention group
Group type: COMPARATOR
Intervention: Phonological processing
Number of subjects: 0
Study 18234152 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonological processing without meaning
Number of subjects: 0
Study 18234152 — intervention group
Group type: COMPARATOR
Intervention: Both phonological and semantic processing
Number of subjects: 0
Study 14722628 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held ultrasound device (HCU)
Number of subjects: 55
Study 14722628 — intervention group
Group type: COMPARATOR
Intervention: Conventional transthoracic echocardiography (TTE)
Number of subjects: 55
Study 10425820 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (N-AC) alone
Number of subjects: 14
Study 10425820 — intervention group
Group type: COMPARATOR
Intervention: N-acetylcysteine (N-AC) combined with activated charcoal (AC)
Number of subjects: 14
Study 7484983 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg
Number of subjects: 45
Study 7484983 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 40 mg
Number of subjects: 45
Study 7484983 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg
Number of subjects: 45
Study 7484983 — intervention group
Group type: COMPARATOR
Intervention: Active placebo (diphenhydramine, 12.5 mg)
Number of subjects: 45
Study 7484983 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine with detectable blood levels
Number of subjects: 45
Study 7484983 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine with no detectable blood levels
Number of subjects: 45
Study 2265137 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 60 mg/m2
Number of subjects: 133
Study 2265137 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin 45 mg/m2 and Vindesine 3 mg/m2 on days 1 and 8 every 4 weeks
Number of subjects: 133
Study 538812 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection of long-acting penicillin (Triplopen)
Number of subjects: 0
Study 538812 — intervention group
Group type: COMPARATOR
Intervention: Five-day course of crystalline and procaine penicillin
Number of subjects: 0
Study 30204244 — intervention group
Group type: EXPERIMENTAL
Intervention: Tick‐E‐Vac vaccine
Number of subjects: 0
Study 30204244 — intervention group
Group type: EXPERIMENTAL
Intervention: EnceVir vaccine
Number of subjects: 0
Study 30204244 — intervention group
Group type: EXPERIMENTAL
Intervention: Tick‐E‐Vac and EnceVir vaccines
Number of subjects: 0
Study 28328712 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein supplementation (25 g)
Number of subjects: 20
Study 28328712 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate supplementation (25 g)
Number of subjects: 20
Study 28328712 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Whey protein and Carbohydrate)
Number of subjects: 20
Study 28328712 — intervention group
Group type: EXPERIMENTAL
Intervention: Detraining (2 weeks)
Number of subjects: 20
Study 26322904 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Treatment of Insomnia (BBTI)
Number of subjects: 77
Study 26322904 — intervention group
Group type: COMPARATOR
Intervention: Information Control (IC)
Number of subjects: 77
Study 26322904 — intervention group
Group type: EXPERIMENTAL
Intervention: NREM delta power
Number of subjects: 77
Study 26322904 — intervention group
Group type: EXPERIMENTAL
Intervention: NREM sigma power
Number of subjects: 77
Study 24636714 — intervention group
Group type: EXPERIMENTAL
Intervention: TEVAR (Cook Zenith TX2)
Number of subjects: 230
Study 24636714 — intervention group
Group type: COMPARATOR
Intervention: Open surgical repair
Number of subjects: 230
Study 23627154 — intervention group
Group type: EXPERIMENTAL
Intervention: Stiletto needle
Number of subjects: 67
Study 23627154 — intervention group
Group type: COMPARATOR
Intervention: Dichofenac Diethylammon
Number of subjects: 67
Study 19416992 — intervention group
Group type: EXPERIMENTAL
Intervention: C reactive protein point of care testing
Number of subjects: 431
Study 19416992 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in enhanced communication skills
Number of subjects: 431
Study 19416992 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (C reactive protein testing and communication skills training)
Number of subjects: 431
Study 19416992 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 431
Study 17302587 — intervention group
Group type: EXPERIMENTAL
Intervention: EC‐MPS 1080 mg bid
Number of subjects: 32
Study 17302587 — intervention group
Group type: COMPARATOR
Intervention: MMF 1500 mg bid
Number of subjects: 32
Study 15127325 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 15 mg
Number of subjects: 389
Study 15127325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 389
Study 11256540 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril plus 25 mg i.v. of canrenoate (1 mg/hour for the first 72 hours and then orally 25 mg/day)
Number of subjects: 187
Study 11256540 — intervention group
Group type: COMPARATOR
Intervention: Captopril alone (placebo)
Number of subjects: 187
Study 10761243 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with psoriasis (PG I, No = 11)
Number of subjects: 38
Study 10761243 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with psoriasis (PG II, No = 27)
Number of subjects: 38
Study 10761243 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with psoriasis (PG I and PG II)
Number of subjects: 38
Study 10761243 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 38
Study 8032582 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg and codeine 30 mg in one combination tablet
Number of subjects: 24
Study 8032582 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg and codeine 60 mg in one combination tablet
Number of subjects: 24
Study 8032582 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg and codeine 30 mg in two separate tablets
Number of subjects: 24
Study 8032582 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg and codeine 60 mg in two separate tablets
Number of subjects: 24
Study 8032582 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 24
Study 8032582 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine 60 mg
Number of subjects: 24
Study 2600323 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine, 150 mg every 12 hours for seven doses
Number of subjects: 23
Study 2600323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 31972302 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve surgery in neonates/infants (n=64)
Number of subjects: 143
Study 31972302 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve surgery in children (n=79)
Number of subjects: 143
Study 30804129 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib at 250 mg/day
Number of subjects: 16
Study 30804129 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib plus bevacizumab at 15 mg/kg every 3 weeks
Number of subjects: 16
Study 28039852 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident delirium
Number of subjects: 469
Study 28039852 — intervention group
Group type: EXPERIMENTAL
Intervention: Restraining devices
Number of subjects: 469
Study 28039852 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital acquired conditions (HACs)
Number of subjects: 469
Study 28039852 — intervention group
Group type: EXPERIMENTAL
Intervention: Other noxious insults
Number of subjects: 469
Study 28039852 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-day mortality
Number of subjects: 469
Study 28039852 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverse probability weighted hazard of death due to delirium
Number of subjects: 469
Study 28039852 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediation effect of potential mediators
Number of subjects: 469
Study 26422724 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarettes containing 2.4 mg of nicotine per gram of tobacco
Number of subjects: 840
Study 26422724 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarettes containing 1.3 mg of nicotine per gram of tobacco
Number of subjects: 840
Study 26422724 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarettes containing 0.4 mg of nicotine per gram of tobacco
Number of subjects: 840
Study 26422724 — intervention group
Group type: COMPARATOR
Intervention: Cigarettes containing 15.8 mg of nicotine per gram of tobacco
Number of subjects: 840
Study 26422724 — intervention group
Group type: COMPARATOR
Intervention: Usual brand of cigarettes
Number of subjects: 840
Study 26422724 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarettes containing 5.2 mg of nicotine per gram of tobacco
Number of subjects: 840
Study 24169161 — intervention group
Group type: EXPERIMENTAL
Intervention: wIRA (water-filtered infrared A irradiation) for 20 minutes preoperatively
Number of subjects: 400
Study 24169161 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 400
Study 24169161 — intervention group
Group type: EXPERIMENTAL
Intervention: wIRA (water-filtered infrared A irradiation)
Number of subjects: 400
Study 21825096 — intervention group
Group type: EXPERIMENTAL
Intervention: UPPP combined with low‐temperature bipolar radiofrequency (group 1)
Number of subjects: 50
Study 21825096 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucosal minimally invasive lingual excision with radiofrequency (SMILE‐R; group 2)
Number of subjects: 50
Study 21825096 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucosal minimally invasive lingual excision with a harmonic scalpel (SMILE‐H; group 3)
Number of subjects: 50
Study 19438864 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin care programme (2-hour training session and occupational advisory service)
Number of subjects: 388